**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2019

Delivery of antibodies into the murine brain via convection-enhanced delivery

Beffinger, Michal Mateusz ; Schellhammer, Linda ; Pantelyushin, Stanislav ; vom Berg, Johannes

Abstract: Convection-enhanced delivery (CED) is a neurosurgical technique enabling effective perfusion of large brain volumes using a catheter system. Such an approach provides a safe delivery method by-passing the blood brain barrier (BBB), thus allowing treatment with therapeutics with poor BBB-permeability or those for which systemic exposure is not desired, e.g., due to toxicity. CED requires optimization of the catheter design, injection protocol, and properties of the infusate. With this protocol we describe how to perform CED of a solution containing up to 20 µg of an antibody into the caudate putamen of mice. It describes preparation of step catheters, testing them in vitro and performing the CED in mice using a ramping injection program. The protocol can be readily adjusted for other infusion volumes and can be used for injecting various tracers or pharmacologically active or inactive substances, including chemotherapeutics, cytokines, viral particles, and liposomes.

DOI: <https://doi.org/10.3791/59675>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-181865>

Journal Article

Published Version

Originally published at:

Beffinger, Michal Mateusz; Schellhammer, Linda; Pantelyushin, Stanislav; vom Berg, Johannes (2019). Delivery of antibodies into the murine brain via convection-enhanced delivery. *Journal of Visualized Experiments (Jove)*, (149):e59675.

DOI: <https://doi.org/10.3791/59675>

Video Article

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Michal Beffinger¹, Linda Schellhammer¹, Stanislav Pantelyushin¹, Johannes vom Berg¹

¹Institute of Laboratory Animal Science, University of Zurich

Correspondence to: Johannes vom Berg at johannes.vomberg@uzh.ch

URL: <https://www.jove.com/video/59675>

DOI: [doi:10.3791/59675](https://doi.org/10.3791/59675)

Keywords: Neuroscience, Issue 149, antibody, neuroscience, brain injection, intracranial, stereotaxic, convection-enhanced delivery, blood brain barrier, brain tumors, glioma, Parkinson's disease, Alzheimer's disease

Date Published: 7/18/2019

Citation: Beffinger, M., Schellhammer, L., Pantelyushin, S., vom Berg, J. Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery. *J. Vis. Exp.* (149), e59675, doi:10.3791/59675 (2019).

Abstract

Convection-enhanced delivery (CED) is a neurosurgical technique enabling effective perfusion of large brain volumes using a catheter system. Such an approach provides a safe delivery method by-passing the blood brain barrier (BBB), thus allowing treatment with therapeutics with poor BBB-permeability or those for which systemic exposure is not desired, e.g., due to toxicity. CED requires optimization of the catheter design, injection protocol, and properties of the infusate. With this protocol we describe how to perform CED of a solution containing up to 20 µg of an antibody into the caudate putamen of mice. It describes preparation of step catheters, testing them in vitro and performing the CED in mice using a ramping injection program. The protocol can be readily adjusted for other infusion volumes and can be used for injecting various tracers or pharmacologically active or inactive substances, including chemotherapeutics, cytokines, viral particles, and liposomes.

Video Link

The video component of this article can be found at <https://www.jove.com/video/59675/>

Introduction

The blood brain barrier (BBB) forms a semipermeable border separating the central nervous system (CNS) from the blood circulation. Reaching the CNS with therapeutics is however necessary in context of various diseases, like brain tumors, Alzheimer's disease (AD) or Parkinson's disease (PD) among others¹. This becomes important in the development of new therapies, especially if the tested drug exhibits poor BBB permeability or its systemic exposure can lead to dangerous toxicity^{1,2}. Some of the clinically used antibodies display both of these features. A solution to this problem would be to deliver the therapeutics directly behind the BBB.

Convection-enhanced delivery (CED) is a neurosurgical technique enabling effective perfusion of large brain volumes. This is achieved by surgically installing one or more catheters in the target area. During the drug application, a pressure gradient is formed at the opening of the catheter, which becomes the driving force of the infusate dispersion in the tissue^{3,4}. It is thus the duration of infusion and not the diffusion coefficients that determine the perfusion range^{2,4,5}. This provides uniform delivery of the infusate over a much larger brain volume compared to conventional, diffusion based intracerebral injection methods^{2,6}. At the same time, this delivery modality has a lower risk of tissue damage². Accordingly, CED can enable safe and efficacious administration of conventional chemotherapeutics for treatment of CNS tumors, as well as delivery of immunomodulatory agents or agonistic and antagonistic antibodies in a multitude of other CNS disorders^{2,7,8,9}. CED is currently tested in therapies of Parkinson's disease, Alzheimer's disease, as well as high-grade glioma^{2,7,8,10,11}.

Catheter design and the injection regimen are among the most important factors influencing the outcome of CED^{10,12,13,14,15,16}. Furthermore, it requires specific physicochemical properties of the infusate, including moderate size of the particles, an anionic charge, and low tissue affinity^{10,17}. Each of these parameters has to be potentially adjusted according to the histological features of the brain region to be targeted^{2,10,17}.

Here we describe methodology for performing CED of an antibody solution into the caudate putamen (striatum) of mice. Furthermore, the protocol includes preparation of step catheters in a laboratory setup, testing them in vitro and performing the CED.

There are multiple catheter designs available in the literature, differing by the shape of the cannula, the materials used and the number of catheter openings^{12,15,18,19,20,21,22}. We are using a step catheter made of a fused silica capillary protruding 1 mm from a blunt end metal needle. This catheter design can be easily manufactured in a research laboratory and reproducibly gives good CED results when tested in vitro with agarose blocks with physical parameters resembling brain parenchyma in vivo²³.

Moreover, we implement a ramping regimen for delivering 5 µL of infusate in vivo. In such a protocol the injection rate is increased from 0.2 µL/min to a maximum of 0.8 µL/min, thus minimizing chances of infusate reflux along the catheter as well as risk of tissue damage¹⁶. Using this protocol, we have successfully administered mice with up to 20 µg of antibody in 5 µL of PBS over the course of 11 min 30 s.

The protocol can be readily adjusted for other infusion volumes or for injecting various other substances, e.g. chemotherapeutics, cytokines, viral particles or liposomes^{2,10,14,18,22}. In case of using infusate with drastically different physicochemical properties compared to a phosphate buffered saline (PBS) or artificial cerebrospinal fluid (aCSF) solution of antibodies, additional validation steps are recommended. For catheter assembly, validation and CED, we describe all steps using a stereotactic robot with a drill and injection unit mounted onto a regular stereotactic frame. This procedure can also be performed with a manual stereotactic frame connected to programmable microinfusion pump that can drive the described glass microsyringes.

Protocol

All methods described here have been approved by the Swiss Cantonal Veterinary Office under license number ZH246/15.

1. Preparation of the Step Catheters

1. Preparation of a fused silica tubing for the step of the catheter

1. Cut the fused silica capillary with inner diameter of 0.1 mm and wall thickness of 0.0325 mm tubing to a length of 30 mm.
2. Examine the tubing for cracks and heat polish the ends using a microforge to ensure the tubing openings have a smooth surface.

2. Fixation of the inner tube in a metal needle

1. Mount a 27 G needle on a 10 μ L syringe and place the syringe in a stereotactic robot.
2. Using the robot, move the syringe over a hard surface and touch it with the needle tip. This position should be noted or saved in the software because it will serve as a reference surface for setting the length of the catheter step.
3. Elevate the needle to enable placing of the fused silica capillary inside of the needle
4. Place the fused silica capillary in the needle such that 20 mm of the capillary is protruding from the needle.
5. Using a pipette, evenly spread 2 μ L of high viscosity cyanoacrylate adhesive over the capillary, starting from the metal needle and finishing 10 mm above the lower end of the capillary, as depicted in **Figure 2**.
6. Using the stereotactic robot, lower the needle until the tip of the metal needle is 1 mm over the reference surface. This way the fused silica capillary will be fixed in the metal needle and will form a 1 mm step from the tip of the metal needle. Remove any excess of glue forming at the end of the metal needle to avoid blunting the step.
7. Wait 15 min for the glue to harden and remove the syringe with the catheter from the stereotactic robot. Confirm that at the step all excess glue has been removed by checking the tip of the catheter under a microscope.

3. Testing the step catheter using a block of agarose

1. Prepare 0.6% agarose solution in PBS in a conventional gel tray and wait until it polymerizes. Cut the agarose in approximately 20 mm x 20 mm blocks. Until use, keep the blocks immersed in PBS.
2. Manually fill the step catheter syringe with 10 μ L of 0.4% solution of filtered trypan blue.
3. Using the stereotactic robot, dispense 1 μ L at 0.2 μ L/min in order to assess sealing of the step of the catheter during the fixation procedure. Trypan blue solution should be visible solely on the tip of the catheter. Wipe it off with a paper tissue.
4. Place the agarose block in the stereotactic robot and calibrate the robot so the tip of the catheter is referenced against the surface of the agarose block.
5. Program the injection parameters for CED.
 1. For the injection volume of 5 μ L, use the following steps: 1 μ L at 0.2 μ L/min, then 2 μ L at 0.5 μ L/min and 2 μ L at 0.8 μ L/min. Adjust the final injection volume according to the specific experimental plan by proportionally changing the duration of each of the steps.
 2. In order to inject the solution into murine caudate putamen (striatum), perform such injection in a position 1 mm frontal and 1.5–2 mm lateral from bregma at the depth of 3.5 mm.
 3. After the injection, leave the catheter in place for 2 min and then retract at 1 mm/min to ensure proper dispersion of the fluid in the brain and sealing of the injection tract during catheter removal.

NOTE: Depending on the specific stereotactic robot used, all the parameters can be programmed into a single script. An example script is available as Supplementary Material.
6. Start the CED procedure and inject 5 μ L of trypan blue solution into the agarose block.
7. Assess the shape of cloud of trypan blue in the agarose and potential leakage along the catheter tract. Trypan blue should form an ellipsoid or a round cloud with the center around the catheter tip and a diameter of at least 1 mm. No major backflow over the tip of the metal needle should be visible.
8. Place a new agarose block and start a second injection of 1 μ L at 0.2 μ L/min in order to assess clogging of the catheter with the agarose. Trypan blue should again start forming a cloud from the tip of the catheter immediately after the start of the injection.
9. Assess whether the leftover volume in the syringe corresponds to 3 μ L. Any variations might point towards a leakage of fluid through the catheter mounting or syringe plunger.
10. If all the test injections are successful, the catheter is well sealed, straight and no trypan blue solution is observed from other spots than the catheter tip, wash the catheter with deionized H₂O (dH₂O) until no traces of trypan blue are visible and then wash ten times as follows: 70% ethanol and 100% ethanol followed by flushing again with 70% ethanol and clean deionized water.
11. Store the catheter under dry conditions.

2. Convection-enhanced Delivery of Antibody Solution into the Murine Brain

NOTE: Depending on local animal welfare regulations, various types of anesthetics, analgesics and antibiotics can be implemented for this procedure. This protocol describes the use of injection anesthesia. Inhalation anesthetics such as isoflurane can also be used by mounting a nose mask on the stereotactic frame. In addition, we recommend adding antibiotics to the drinking water for infection prophylaxis.

1. Surgical setup

1. Prepare anesthetics and antidote solutions. Mice can be safely anesthetized using a three-component anesthesia containing fentanyl (0.05 mg/kg), midazolam (5 mg/kg) and medetomidine (0.5 mg/kg) diluted in sterile dH₂O. We perform a two-step wake up procedure using two antidote solutions, one containing flumazenil (0.5 mg/kg) and buprenorphine (0.1 mg/kg) in sterile dH₂O (first antidote solution). The second one contains atipamezole (2.5 mg/kg) in sterile dH₂O (second antidote solution).
2. Prepare analgesia solution containing carprofen (5.667 mg/kg) diluted with sterile dH₂O.
3. Clean the stereotactic frame, heating pad and elements of the stereotactic robot. Bear in mind that not all the parts of the robot can be cleaned without risk of damage. Refer to the manual of the robot for details on cleaning and preparing for usage.
4. Assemble the syringe with the step catheter and flush it multiple times with dH₂O, 70% ethanol and 100% ethanol followed by flushing again with 70% ethanol and dH₂O. Finally, flush the syringe with PBS or other buffers to be used for preparation of the solution for intracranial injection, e.g. artificial cerebrospinal fluid. The plunger of the syringe should move smoothly and freely during the whole procedure.
5. Calibrate the stereotactic robot software with the stereotactic frame.
6. Test the stereotactic robot software by ensuring that the robot arms move freely and that the injection pump is properly connected and can perform the CED procedure without any disturbances. This includes testing robot movement, ramping injection, checking the 2 min waiting step and the speed of catheter retraction. All the parameters should fit the preprogrammed CED procedure described in point 1.3.5.
7. Insert the drill bit in the drill. It is recommended to sterilize the drill bits before use.
8. Prepare antibody solution using PBS or other buffer solutions such as aCSF. 1 to 20 µg of antibody in 5 µL can be injected in a single CED procedure. Other volumes and protein amounts should be tested prior to performing the experiment. Be aware that using high viscosity solutions might lead to catheter clogging.
9. Manually load the syringe with the diluted antibody.

2. Antibody injection by CED into striatum

1. Weigh the mouse and inject the three-component anesthesia solution into the peritoneum according to the body weight. Note the injection time. Transfer the mouse to a separate cage heated with a heating pad.
2. Observe the mouse to determine when the sedation starts. As soon as the mouse stops moving, apply ophthalmic ointment on the eyes to protect the cornea from drying out during the surgery. Full sedation usually starts 10–15 min from the injection of the three-component anesthesia solution.
3. Check pain reactions using the pinch-reflex test to ensure full anesthesia of the animal.
4. Shave the head using a hair trimmer.
5. Disinfect the skin with cotton swabs soaked in iodine solution. Scrub the skin three times in circular motion.
6. Using a scalpel, make a 10 mm skin incision along the cranial midline finishing on the eye level.
7. Fix the mouse in the stereotactic frame using the nose clamp and ear bars. Ensure that the skull surface is horizontal and tightly secured. Apart from correct anatomical navigation this is also crucial to avoid tilting of the skull during the drilling and the CED procedure.
8. Place the syringe in the stereotactic robot.
9. Synchronize the drill bit with the tip of the catheter on a reference point. It is crucial that the relation between the position of the drill and the syringe is precisely determined in the software, so the injection can be performed in the desired anatomical region of the brain.
10. Retract the skin using forceps and localize bregma on the skull surface.
11. Reference bregma in the software using the tip of the drill bit.
12. Move the drill to a position 1 mm frontal and 2 mm lateral from bregma and drill a burr hole. Be careful not to damage the dura mater.
13. Move the syringe over the burr hole.
14. Dispense 0.5–1 µL from the syringe to ensure that no air bubbles are left in the catheter.
15. Start the CED program described in point 1.3.5. Observe the skull surface for any traces of fluid backflow from the injection spot. Monitor the breathing rate of the animal.
16. Once the CED program is over and the catheter is withdrawn from the brain, start the injection pump at 0.2 µL/min in order to check for catheter clogging during the CED. If no clogging occurred, you should immediately see a droplet of injection mix coming from the catheter tip.
17. Prior to reusing or storing the catheter, visually examine the catheter step for any signs of damage or wear under a microscope and clean it as in step 1.3.10.

3. Waking up procedure

1. Gently remove the mouse from the stereotactic frame.
2. Wash the surgery site with sterile saline solution.
3. Using forceps, fill the burr hole with bone wax.
4. Close the skin with thin-tipped forceps and apply surgical glue with a 10 µL pipette over the cut. Wait 15–30 s for the glue to polymerize.
5. Apply analgesia solution by subcutaneous injection. Note the time of injection.
6. Apply the first antidote solution. Note the time of injection.
7. Transfer the mouse to a separate cage with a heating pad and monitor the animal for startle reflexes.
8. If mouse has not gained full consciousness 15 min after administration of the first antidote solution, apply the second antidote solution by subcutaneous injection.

9. Monitor animals during recovery phase.
10. Check 1–2 h later as well as the next day for post-operative complications. If necessary, re-apply the analgesia.
11. For infection prophylaxis, add sulfadoxin (final concentration 0.08% w/v) and trimethoprim (final concentration 0.016% w/v) to drinking water to which the animals have access ad libitum for 1 week after the surgery.

Representative Results

This protocol enables preparation of step catheters (**Figure 1**) for use in the CED procedure in a laboratory environment. In order to control the catheters for leakage, reflux along the needle tract and clogging, we recommend performing injections of a dye, e.g., trypan blue solution, into an agarose block. **Figure 3** depicts a cloud of trypan blue forming after injection of 1 μ L at 0.5 μ L/minute using a CED catheter (**Figure 3A**). No reflux along the needle tract was visible over the beginning of the catheter step. Furthermore, the dispersed cloud formed a desired spherical shape. This is in contrast with the results obtained using a conventional 27 G blunt end needle (**Figure 3B**), where significant reflux could be observed.

Moreover, CED requires an optimized injection procedure. **Figure 4** shows the results of injecting 2 μ L of trypan blue into an agarose block using the ramping procedure described in the protocol (A) compared to an injection at a steady rate of 2 μ L/minute (B). High injection speed forced the reflux along the catheter even when a CED catheter was being used.

Finally, as shown in **Figure 5**, CED enables perfusion of large volumes of the murine brain. Mice were injected with a rat anti-mouse TNF α antibody combined with FITC-dextran in 5 μ L of PBS by CED (upper panel) or by a conventional bolus injection (bottom panel). The perfusion profile of CED was more uniform than of conventional injection and less tissue damage could be observed. In both cases there was a typical distribution profile of antibody and dextran particles over the corpus callosum. However, the dispersion profile of the injected antibody was more diffuse than of the high molecular weight dextran, exemplifying differences in distribution between different infusates.

Figure 1: A schematic drawing showing the CED step catheter tip. Frontal (A) and side (B) views. Scheme is not up to scale. [Please click here to view a larger version of this figure.](#)

Figure 2: A schematic drawing depicting the application area of the adhesive. The upper 10 mm of the fused silica tubing are inserted in the metal needle. Apply the adhesive on the 10 mm of tubing starting from the tip of the metal needle. [Please click here to view a larger version of this figure.](#)

Figure 3: Comparison of infusion results using CED catheter or a blunt-end needle. Injection of 1 μ L of 0.4% trypan blue into an 0.6% agarose block at 0.5 μ L/minute using a CED catheter (A) and a 27G blunt-end needle (B). Pictures taken immediately after the catheter or needle withdrawal. Cross marks the tip of the catheter or needle. Scale bar = 5 mm. [Please click here to view a larger version of this figure.](#)

Figure 4: Comparison of infusion results of ramping CED protocol with steady rate protocol. Injection of 2 μ L of 0.4% trypan blue into 0.6% agarose block using a ramping CED protocol (0.4 μ L at 0.2 μ L/min, then 0.8 μ L at 0.5 μ L/min and 0.8 μ L at 0.8 μ L/min (A) or a 2 μ L/min steady rate injection protocol (B). In both cases a CED catheter was used. Pictures taken immediately after the catheter withdrawal. Cross marks the tip of the catheter. Scale bar = 5 mm. [Please click here to view a larger version of this figure.](#)

Figure 5: Representative results of murine striatum perfusion by CED or by conventional bolus injection. Mice were injected into the striatum (position 1 mm frontal and 2 mm lateral from bregma, depth of 3.5 mm) with 1 μ g of rat anti-mouse TNF α combined with 1 μ g of FITC-Dextran with the molecular weight 2,000 kDa in 5 μ L of PBS. CED protocol (upper panel) or a conventional bolus injection (27 G needle, injection rate 1 μ L/minute) was performed (bottom). Mice were sacrificed immediately after the CED procedure by controlled CO₂ asphyxiation and perfused with 4% formaldehyde in PBS. Brains were dissected and additionally fixed with 4% formaldehyde in PBS at 4 °C for 24 h. Subsequently, brains were washed with 15% sucrose for 60 min and transferred to 30% sucrose at 4 °C. After 24 h, brains were frozen on dry ice. Free-floating sections (25 μ m) were stained using polyclonal goat anti-rat IgG (H+L) antibody coupled with Alexa Fluor 647 and counterstained with DAPI. Images were processed using the Fiji distribution of ImageJ. 10x magnification, Scale bar = 5 mm. 4 mice per group; a representative picture is shown. [Please click here to view a larger version of this figure.](#)

Discussion

Convection-enhanced delivery, or pressure-mediated drug infusion into the brain, was first proposed in the early 1990³. This approach promises perfusion of large brain volumes behind the blood brain barrier in a controlled manner². However, so far, only a few clinical trials have been performed using this approach, partially because CED in a clinical setup has shown to be technically demanding^{24,25}. Recent developments in the catheter design and infusion programs seem to have overcome these technical difficulties^{8,19}. Progress made in clinical implementation of therapeutic antibodies, including the advent of immunomodulatory checkpoint blocking agents, awaits application in the treatment of CNS disorders¹⁰. This development can be greatly augmented by employing CED in the experimental setup, such as using small rodent models.

Various CNS disease models are available in mice. These include experimental autoimmune encephalomyelitis (EAE) for multiple sclerosis (MS) and genetically engineered models for Alzheimer's disease (AD), Parkinson's disease (PD), or for brain cancer. Many brain tumor models also rely on orthotopic tumor inoculation of murine glioma cell lines or implantation of patient-derived xenografts. This protocol enables delivery of antibody solutions directly into specific anatomic locations, thus resembling therapeutic procedures. It can be implemented in various experimental layouts where delivery of antibody into a precise brain region plays a pivotal role.

The critical factor in performing CED in mice is the availability of catheters. This protocol contains a precise description how to assemble a step catheter and test it in a series of in vitro experiments. One should bear in mind that the fused silica of which the step tubing is made is a brittle material and the quality of CED with a given catheter might decline over time. It is recommended to control the parameters of the step catheters in between the in vivo experiments by repeating the in vitro tests described in the protocol section 1.3.

The protocol can be adjusted for different injection volumes, types of infusate and brain regions. The injection volume can be manipulated by proportionally changing the duration of the injection steps. Here we describe infusion of 5 μ L, but CED with 10 μ L of antibody solution has been reported in the literature using a similar approach in murine brain tumor models, achieving excellent tissue distribution and perfusion volumes vastly exceeding bolus injection⁷. Furthermore, up to 28 μ L infusate volumes have been reported using CED for application of liquids into the rat brain^{22,26}. Non-proteinaceous substances can also be injected by CED, keeping in mind that the infusate should not be of high viscosity to avoid clogging of the narrow catheter tip. Using liposomes, it has been demonstrated that the charge of the infused molecules can vastly influence the tissue penetration, with neutral or negatively charged particles being able to be distributed over the largest volumes²². As depicted in **Figure 5**, FITC-dextran and antibody disperse differently: although both antibody and FITC-dextran distribute similarly along the corpus callosum, the antibody penetration of brain parenchyma is more diffuse than for FITC-dextran, which shows a smaller radius and a more spotty distribution pattern. This underlines the differences in CED profile between infusates with varying physicochemical properties.

Furthermore, the CED experiment described here and shown in **Figure 5** was performed injecting an anti-mouse TNF α antibody into healthy mice, so assuming minimal target amount in the striatum. Presence of cognate antigen will change the tissue distribution pattern. It can be further affected by inhomogeneous tissue at an anatomical site, as depicted in **Figure 5** by distribution of the infusate along the corpus callosum.

Finally, CED is affected by the flow of interstitial fluid, which in the case of striatum injection, can flush the infusate towards the lateral ventricles²⁷. Indeed, even when the tissue is fixed immediately after finishing CED, we can observe a marked adhesion of the injected antibody to the ventricle wall (**Figure 5**). This can be further affected by pathological conditions of the CNS, e.g. in context of brain tumors. Focal necrosis, often observed in high grade brain tumors²⁸, can affect the flow of interstitial fluid and thus alter the distribution pattern of the infusate²⁹. Other pathological conditions that can lead to changed tissue distribution of infusate as compared to healthy parenchyma include stroke or traumatic brain injury³⁰. To sum up, every series of CED experiments has to be carefully validated to ensure successful perfusion of the target brain region.

Currently, researchers frequently use implantable osmotic pumps to deliver substances into the CSF or brain (tumor) parenchyma^{31,32,33}. In certain cases CED as described here can be used as an alternative. It can be performed multiple times with frequencies depending on the brain region, type of infusate, volume and anesthesia protocol used. Intermittent drug delivery can be particularly relevant when an extended exposure to the infusate leads to tolerance or systemic side effects. It is conceivable that in cases where high retention and half-life infusates are being delivered, this approach would represent a refinement according to the 3R principle since no pump implantation would be necessary. In conclusion, this protocol describes an efficient way of infusing large volumes of antibody solution into the murine striatum and can be adjusted for other brain regions and types of infusate.

Disclosures

Johannes vom Berg is mentioned as an inventor on patent application (PCT/EP2012/070088) of the University of Zurich. Michal Beffinger, Linda Schellhammer and Johannes vom Berg are mentioned as inventors on a patent application (EP19166231) of the University of Zurich. The authors have no additional financial interests.

Acknowledgments

This work was supported by grants of the University of Zurich (FK-15-057), the Novartis Foundation for medical-biological Research (16C231) and Swiss Cancer Research (KFS-3852-02-2016, KFS-4146-02-2017) to Johannes vom Berg and BRIDGE Proof of Concept (20B1-1_177300) to Linda Schellhammer.

References

- Scherrmann, J. M. Drug delivery via the blood-brain barrier. *Vascular Pharmacology*. **38** (6), 349-354 (2002).
- Barua, N. U., Gill, S. S. Convection-enhanced drug delivery: prospects for glioblastoma treatment. *CNS Oncology*. **3** (5), 313-316 (2014).
- Bobo, R.H. et al. Convection-enhanced delivery of macromolecules in the brain. *Proceedings of the National Academy of Sciences of the United States of America*. **91** (6), 2076-2080 (1994).
- Morrison, P. F., Laske, D. W., Bobo, H., Oldfield, E. H., Dedrick, R. L. High-flow microinfusion: tissue penetration and pharmacodynamics. *American Journal of Physiology*. **266** (1 Pt 2), R292-305 (1994).
- Zhou, Z., Singh, R., Souweidane, M. M. Convection-Enhanced Delivery for diffuse intrinsic pontine glioma treatment. *Current Neuropharmacology*. **15** (1), 116-128 (2017).
- Barua, N. U. et al. Intrastriatal convection-enhanced delivery results in widespread perivascular distribution in a pre-clinical model. *Fluids and Barriers of the CNS*. **9** (1), 2 (2012).
- Shoji, T. et al. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. *Neuro-Oncology*. **18** (8), 1120-1128 (2016).
- Souweidane, M. M. et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. *The Lancet Oncology*. (2018).
- Zhang, X. et al. Targeting immune checkpoints in malignant glioma. *Oncotarget*. **8** (4), 7157-7174 (2017).
- Barua, N. U., Gill, S. S., Love, S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. *Brain Pathology*. **24** (2), 117-127 (2014).
- Mehta, A. M., Sonabend, A. M., Bruce, J. N. Convection-Enhanced Delivery. *Neurotherapeutics*. **14** (2), 358-371 (2017).

12. Krauze, M. T. et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. *Journal of Neurosurgery*. **103** (5), 923-929 (2005).
13. Nash, K. R., Gordon, M. N. Convection Enhanced Delivery of Recombinant Adeno-associated Virus into the Mouse Brain. *Methods in Molecular Biology*. **1382** 285-295 (2016).
14. Ohlfest, J. R. et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. *Molecular Therapy*. **12** (5), 778-788 (2005).
15. Yin, D., Forsayeth, J., Bankiewicz, K. S. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. *Journal of Neuroscience Methods*. **187** (1), 46-51 (2010).
16. Mamot, C. et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. *Journal of Neuro-Oncology*. **68** (1), 1-9 (2004).
17. Saito, R. et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. *Journal of Neuroscience Methods*. **154** (1-2), 225-232 (2006).
18. Oh, S. et al. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. *Journal of Neurosurgery*. **107** (3), 568-577 (2007).
19. Barua, N. U. et al. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. *Drug Delivery*. **23** (1), 167-173 (2016).
20. Rosenbluth, K. H. et al. Design of an in-dwelling cannula for convection-enhanced delivery. *Journal of Neuroscience Methods*. **196** (1), 118-123 (2011).
21. Debinski, W., Tatter, S. B. Convection-enhanced delivery for the treatment of brain tumors. *Expert Review of Neurotherapeutics*. **9** (10), 1519-1527 (2009).
22. MacKay, J. A., Deen, D. F., Szoka, F. C., Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. *Brain Research*. **1035** (2), 139-153 (2005).
23. Chen, Z. J. et al. A realistic brain tissue phantom for intraparenchymal infusion studies. *Journal of Neurosurgery*. **101** (2), 314-322 (2004).
24. Sampson, J. H. et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. *Journal of Neurosurgery*. **113** (2), 301-309 (2010).
25. Wick, W., Weller, M. Trabectedin to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). *Neuro-Oncology*. **13** (5), 559-560; author reply 561-552 (2011).
26. Saito, R., Tominaga, T. Convection-enhanced delivery of therapeutics for malignant gliomas. *Neurologia Medico-Chirurgica*. **57** (1), 8-16 (2017).
27. Bedussi, B. et al. Clearance from the mouse brain by convection of interstitial fluid towards the ventricular system. *Fluids Barriers CNS*. **12** 23 (2015).
28. Noroxe, D. S., Poulsen, H. S., Lassen, U. Hallmarks of glioblastoma: a systematic review. *ESMO Open*. **1** (6), e000144 (2016).
29. Boucher, Y., Salehi, H., Witwer, B., Harsh, G. R. t., Jain, R. K. Interstitial fluid pressure in intracranial tumours in patients and in rodents. *British Journal of Cancer*. **75** (6), 829-836 (1997).
30. Glushakova, O. Y. et al. Prospective clinical biomarkers of caspase-mediated apoptosis associated with neuronal and neurovascular damage following stroke and other severe brain injuries: Implications for chronic neurodegeneration. *Brain Circulation*. **3** (2), 87-108 (2017).
31. Vom Berg, J. et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. *Nature Medicine*. **18** (12), 1812-1819 (2012).
32. Vom Berg, J. et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. *Journal of Experimental Medicine*. **210** (13), 2803-2811 (2013).
33. Kurdi, A. et al. Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice. *British Journal of Pharmacology*. **173** (23), 3359-3371 (2016).